Enteric-coated Mycophenolate sodium (EC-MPS)

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

De Novo Kidney Transplant

Conditions

De Novo Kidney Transplant

Trial Timeline

Apr 1, 2004 → —

NCT ID

NCT00284921

About Enteric-coated Mycophenolate sodium (EC-MPS)

Enteric-coated Mycophenolate sodium (EC-MPS) is a phase 3 stage product being developed by Novartis for De Novo Kidney Transplant. The current trial status is terminated. This product is registered under clinical trial identifier NCT00284921. Target conditions include De Novo Kidney Transplant.

What happened to similar drugs?

9 of 15 similar drugs in De Novo Kidney Transplant were approved

Approved (9) Terminated (0) Active (6)

✅Tacrolimus targeted half-dose + Tacrolimus targeted plain doseAstellas PharmaApproved

✅Prograf + AdvagrafAstellas PharmaApproved

✅ATG-FAstellas PharmaApproved

✅Advagraf + Prograf + Corticosteroid + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus targeted half-dose + Tacrolimus targeted plain doseAstellas PharmaApproved

✅Enteric-coated Mycophenolate sodium (EC-MPS)NovartisApproved

✅Enteric-Coated Mycophenolate Sodium (EC-MPS)NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00405652	Phase 3	Completed	Jan 1, 2007	Sep 1, 2008	Liver Transplantation
NCT00529269	Approved	Completed	Dec 1, 2006	—	Renal Transplant
NCT00369278	Phase 3	Completed	Jun 1, 2006	Dec 1, 2008	Renal Transplantation
NCT00537862	Approved	Completed	May 1, 2006	—	Kidney Transplant
NCT00267150	Phase 3	Completed	Nov 1, 2005	Jan 1, 2008	Pancreas Transplantation
NCT00149968	Approved	Completed	Apr 1, 2005	Jan 1, 2007	Renal Transplantation
NCT00238953	Approved	Completed	Feb 1, 2005	Jun 1, 2006	Renal Transplantation
NCT00239083	Approved	Completed	Jan 1, 2005	Aug 1, 2006	Kidney Transplantation
NCT00149942	Approved	Completed	Oct 1, 2004	Aug 1, 2006	Kidney Transplantation
NCT00150020	Approved	Completed	Oct 1, 2004	—	Renal Transplantation
NCT00154206	Approved	Completed	Sep 1, 2004	—	Kidney Transplantation
NCT00154232	Approved	Completed	Jun 1, 2004	—	Renal Transplantation
NCT00150007	Approved	Completed	Jun 1, 2004	—	Kidney Maintenance Transplant
NCT00284921	Phase 3	Terminated	Apr 1, 2004	—	De Novo Kidney Transplant
NCT00240955	Approved	Completed	Mar 1, 2004	May 1, 2006	Renal Transplantation
NCT00312143	Approved	Completed	Feb 1, 2004	Oct 1, 2005	De Novo Kidney Transplant Recipients
NCT00154245	Approved	Completed	Jan 1, 2004	Mar 1, 2006	Kidney Transplantation
NCT00239070	Phase 3	Completed	Apr 1, 2003	May 1, 2006	Renal Transplantation
NCT00239018	Approved	Completed	Apr 1, 2003	Jul 1, 2005	De Novo Kidney Transplantation
NCT00238940	Phase 3	Completed	Feb 1, 2003	Sep 1, 2005	Renal Transplantation

Competing Products

19 competing products in De Novo Kidney Transplant

See all competitors

Product	Company	Stage	Hype Score
Alefacept + placebo + Tacrolimus + Mycophenolate Mofetil + Steroids	Astellas Pharma	Phase 2	35
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	39
Prograf + Advagraf	Astellas Pharma	Approved	43
ATG-F	Astellas Pharma	Approved	43
Advagraf + Prograf + Corticosteroid + Mycophenolate mofetil	Astellas Pharma	Approved	43
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	39
Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase	AbbVie	Phase 1	36
Birabresib Dose 20 mg	Merck	Phase 1	21
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	43
Enteric-Coated Mycophenolate Sodium (EC-MPS)	Novartis	Approved	43
everolimus + cyclosporine + Prednison (continuous steroids)	Novartis	Phase 3	40
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	40
AEB071	Novartis	Phase 1	29
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
EC-MPS	Novartis	Phase 3	40
Enteric-coated Mycophenolate sodium (EC-MPS), valsartan	Novartis	Phase 3	40
everolimus	Novartis	Phase 3	40
Prograf + Tacrolimus Hexal	Novartis	Approved	43
Mycophenolate Mofetil	Roche	Approved	43